
-
Kala Pharmaceuticals NASDAQ:KALA Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
Location: 490 Arsenal Way, Suite 120, Massachusetts, 02472, US | Website: kalarx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
15.27M
Cash
54.2M
Avg Qtr Burn
-7.677M
Short % of Float
1.35%
Insider Ownership
5.14%
Institutional Own.
48.13%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EYSUVIS™ (loteprednol etabonate ophthalmic suspension) Details Dry Eye Disease | Approved Quarterly sales | |
INVELTYS™ (loteprednol etabonate ophthalmic suspension) Details Post-operative ocular inflammation and pain | Approved Quarterly sales | |
KPI-012 Details Persistent Corneal Epithelial Defect | Phase 2b Data readout |